Drug intelligence / Profile preview

polymyxin B sulfate + bacitracin zinc + hydrocortisone + neomycin sulfate

Development stage
Approved
Lead developer
Bausch + Lomb
Modality
Small Molecules, Peptides
Administration
Ophthalmic
01

Overview

**Polymyxin B sulfate + bacitracin zinc + hydrocortisone + neomycin sulfate** is a fixed-dose, sterile ophthalmic antibiotic-corticosteroid ointment marketed as **Cortisporin Ophthalmic Ointment**. Neomycin inhibits bacterial protein synthesis through the 30S ribosomal subunit; polymyxin B disrupts susceptible Gram-negative bacterial outer membranes through binding to lipopolysaccharide lipid A; bacitracin inhibits bacterial cell-wall synthesis by blocking recycling of the undecaprenyl pyrophosphate lipid carrier; and hydrocortisone activates glucocorticoid receptors to suppress ocular inflammation. It is indicated for steroid-responsive inflammatory ocular conditions in which bacterial infection is present or poses a meaningful risk, including inflammatory conditions involving the conjunctiva, cornea, and anterior segment, chronic anterior uveitis, and certain corneal injuries. The product has activity against several common ocular bacterial pathogens but does not provide adequate coverage against *Serratia marcescens*. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50416slr015_cortisporin_lbl.pdf))

Brand names
Cortisporin Ophthalmic Ointment
Other names
neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone ophthalmic ointmentneomycin sulfate + polymyxin B sulfate + bacitracin zinc + hydrocortisone
02

Targets

Bacterial RibosomeGR (Glucocorticoid receptor)C55-PP (Undecaprenyl pyrophosphate)Lipid A component of bacterial lipopolysaccharide

Beyond the preview

Go deeper on polymyxin B sulfate + bacitracin zinc + hydrocortisone + neomycin sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polymyxin B sulfate + bacitracin zinc + hydrocortisone + neomycin sulfate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call